Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial.
| Author | |
|---|---|
| Abstract | :
IL-22 promotes epidermal hyperplasia and inhibits skin barrier function. |
| Year of Publication | :
2018
|
| Journal | :
Journal of the American Academy of Dermatology
|
| Date Published | :
2018
|
| ISSN Number | :
0190-9622
|
| URL | :
http://linkinghub.elsevier.com/retrieve/pii/S0190-9622(18)30101-4
|
| DOI | :
10.1016/j.jaad.2018.01.016
|
| Short Title | :
J Am Acad Dermatol
|
| Download citation |